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tion of the hypoxia inducible factor 1a (HIF-1a), which consti-
tutes a target for angiogenic gene therapy. However, gene
therapy is hampered by low gene delivery efficiency and non-
specific side effects. Here, we developed a gene transfer tech-
nique based on magnetic targeting of magnetic nanoparticle-
lentivirus (MNP-LV) complexes allowing site-directed gene
delivery to individual wounds in the dorsal skin of mice. Using
this technique, we were able to control HIF-1a dependent
wound healing angiogenesis in vivo via site-specific modulation
of the tyrosine phosphatase activity of SHP-2. We thus uncover
a novel physiological role of SHP-2 in protecting HIF-1a from
proteasomal degradation via a Src kinase dependent mecha-
nism, resulting in HIF-1a DNA-binding and transcriptional
activity in vitro and in vivo. Excitingly, using targeting of
MNP-LV complexes, we achieved simultaneous expression of
constitutively active as well as inactive SHP-2 mutant proteins
in separate wounds in vivo and hereby specifically and locally
controlled HIF-1a activity as well as the angiogenic wound heal-
ing response in vivo. Therefore, magnetically targeted lentiviral
induced modulation of SHP-2 activity may be an attractive
approach for controlling patho-physiological conditions relying
on hypoxic vessel growth at specific sites.
INTRODUCTION
Angiogenic gene therapy shows great potential in improving ischemic
cardiovascular disease1,2 and wound healing,3 while anti-angiogenic
gene therapy is a promising approach to inhibit tumor growth4 and
ocular disease.5 Themain hurdles with this technique yet to overcome
are poor gene delivery and expression efficiency at the desired site and
non-specific distribution of the therapeutic genes. Due to their low
immunogenicity, high efficiency in transfecting non-dividing cells,
and long-term expression profile, lentiviruses may represent an effec-
tive gene delivery system for endothelial and thus angiogenic gene1616 Molecular Therapy Vol. 25 No 7 July 2017 ª 2017 The Americantherapy. By combining therapeutic lentiviral vectors with a targeting
system, therapeutic gene expression exclusively at desired sites may be
achieved and non-specific distribution prevented. Superparamagnetic
nanoparticles (MNP) have been shown to successfully target DNA
vectors or small interfering (si)RNA to several cell types and tissues
upon magnetic field exposure6–8 and show favorable characteristics
for in vivo application, such as low cytotoxicity.9 Magnetically guided
lentiviral gene delivery, using MNP associated to lentiviruses, has
repeatedly been used by us to efficiently transfect cells in vitro and
target reporter gene expression in vivo.10–12 Thus, lentiviral MNP
may represent an efficient approach to manipulate physiological pro-
cesses in vivo. However, magnetic targeting of therapeutic lentiviral
MNP has not yet been tested for its ability to specifically control
angiogenesis in vivo.
A condition, which is a strong inducer of angiogenesis thereby
influencing for instance wound healing, tumor growth, and diabetic
retinopathy,13,14 is hypoxia. The responsible factor for these angio-
genic responses is the transcription factor hypoxia inducible factor
1 (HIF-1), consisting of the subunits HIF-1a and HIF-1b. In a
normoxic environment, HIF-1a is rapidly degraded by the protea-
some due to hydroxylation of two proline residues by the prolyl
hydroxylase domain containing enzymes (PHD). Under hypoxic
conditions, HIF-1a accumulates and induces expression of several
angiogenic genes through binding to hypoxia responsive elementsSociety of Gene and Cell Therapy.
www.moleculartherapy.org(HRE) in the promotor region.14,15 Due to the absolute importance
of HIF-1a within this context, it has been the target of therapeutic
strategies aiming at either inducing vessel growth, as in the case of
diabetic wound healing16,17 and limb ischemia,18 or inhibiting
vessel formation to impair tumor growth19,20 or retinal neovascula-
rization.21 Therefore, factors regulating HIF-1a expression or activ-
ity may in addition be of interest for therapeutic approaches.
Previously, we showed that the tyrosine phosphatase SHP-2 regu-
lates growth factor dependent vessel formation,22 and in an earlier
study, Saxton et al.23 found SHP-2 to influence the formation of the
vascular network of the yolk sac in mice embryos. However, it is
still unknown if SHP-2 plays a role in hypoxic angiogenesis. In
addition, an influence of SHP-2 on HIF-1a stabilization and activa-
tion has never been investigated. Furthermore, no studies regarding
the potential of SHP-2 as therapeutic target for angiogenic therapy
has been performed.
Therefore, we established an in vivo model, where complexes of
therapeutic lentiviruses and MNP were targeted to individual sites
within the same tissue to differentially influence wound healing
angiogenesis and to study the role of SHP-2 in this process. We
found SHP-2 to be essential for hypoxic angiogenesis by inhibiting
HIF-1a degradation through Src activation resulting in HIF-1a
DNA-binding and transcriptional activity in vitro as well as in vivo.
Excitingly, by using complexes of lentiviral vectors and magnetic
nanoparticles, we induced the simultaneous expression of constitu-
tively active as well as inactive SHP-2 mutant proteins in separate
wounds within the same tissue in mice, thus specifically and locally
controlling the response to wound healing angiogenesis and
HIF-1a activity in vivo. Thus, magnetic site-directed genetic mod-
ulation of SHP-2 activity may constitute a potent approach to
empower controlled modulation or fine-tuning of angiogenesis at
specific sites.
RESULTS
Loss of SHP-2 Phosphatase Activity Impairs Angiogenesis and
HIF-1a Stabilization under Hypoxic Conditions In Vitro
To investigate the influence of SHP-2 on angiogenic processes under
hypoxia, endothelial cells were lentivirally transduced with myc-
tagged SHP-2 wild-type (WT), a dominant negative SHP-2 mutant
(CS), where the critical cysteine 459 in the phosphatase domain
was exchanged for serine, or a constitutively active SHP-2 (E76A)
(Figure S1). Endothelial cells overexpressing SHP-2 CS showed a
significantly impaired proliferation during hypoxic conditions,
whereas overexpression of SHP-2 E76A resulted in enhanced pro-
liferation compared to cells overexpressing the SHP-2 WT construct
(p < 0.05, n = 5 in triplicates; Figure 1A). However, treatment of
SHP-2 E76A cells with the HIF-1a inhibitor echinomycin24 pre-
vented the increase in proliferation previously observed in these cells
(p < 0.05, n = 5 in triplicates). Moreover, expression of SHP-2 CS
significantly reduced the formation of capillary like structures in
Matrigel, whereas SHP-2 E76A expression even enhanced this
compared to cells expressing SHP-2 WT (both p < 0.05, n = 5
each 4 fields of view; Figure 1B). Importantly, SHP-2 CS expressionresulted in impaired hypoxic vessel sprouting from aortic segments
ex vivo, while SHP-2 E76A expression enhanced this compared to
SHP-2 WT (p < 0.05, n = 4; Figure 1C). Finally, hypoxia-induced
production of the angiogenic factor vascular endothelial growth fac-
tor (VEGF) was impaired in SHP-2 CS cells and enhanced in SHP-2
E76A cells compared to SHP-2 WT (p < 0.05, n = 3–6; Figure 1D).
Having observed that SHP-2 affects angiogenic responses under
hypoxia, we further investigated if SHP-2 influences hypoxic
HIF-1a accumulation in endothelial cells in vitro. Whereas hypoxic
treatment increased HIF-1a protein levels in SHP-2 WT expressing
endothelial cells, SHP-2 CS expression decreased and SHP-2 E76A
expression enhanced hypoxia-induced HIF-1a levels significantly
(p < 0.05, n = 6; Figure 1E). In contrast, the expression of a
SHP-2 construct with mutations of both its tyrosine phosphoryla-
tion sites (Y542/580F, Y2F) did not influence HIF-1a accumulation,
proving the observed effects being exclusively dependent on SHP-2
phosphatase activity. Furthermore, promotor binding activity of
HIF-1a was reduced in nuclear extracts of SHP-2 CS cells compared
to SHP-2 WT cells (p < 0.05, n = 3 in duplicates; Figure 1F). Like-
wise, double transduction of endothelial cells with SHP-2 mutant
constructs in combination with a lentiviral HIF1-transcriptional
reporter construct (HIF1-TRE-Luc) containing HIF-1 transcrip-
tional response elements (TRE) or control reporter construct lacking
the TRE (Control-Luc), respectively, revealed a 2-fold increase in
luciferase activity upon hypoxia in SHP-2 WT cells, which was
completely inhibited upon SHP-2 CS expression (p < 0.05, n = 5;
Figure 1G).
SHP-2 Prevents Degradation of HIF-1a under Hypoxic
Conditions via Src Kinase Activation
Induction of HIF-1a protein levels can result from increased gene
expression or inhibition of its degradation.25 To elucidate how
SHP-2 activity regulates HIF-1a protein levels, we therefore first
measured HIF-1a mRNA levels in hypoxic cells expressing the
different SHP-2 mutants. Quantitative real-time PCR did not reveal
any difference in HIF-1a mRNA expression between SHP-2 WT,
CS, and E76A expressing cells upon hypoxic treatment (n = 3 in du-
plicates; Figure 2A). Live cell detection of HIF-1a mRNA using
SmartFlare probes in these cells confirmed this finding (n = 3 in du-
plicates; Figure 2B). To investigate if SHP-2 instead influences
HIF-1a degradation, SHP-2 WT and CS cells were treated with the
proteasome inhibitorsMG132 and epoxomicin, respectively. Hypoxia
increased HIF-1a levels in SHP-2WT cells (p < 0.05, n = 7; Figure 2C)
and, as observed in previous experiments (Figure 1E), SHP-2 CS over-
expression led to decreased HIF-1a protein accumulation (p < 0.05,
n = 7). Interestingly, treatment of hypoxic SHP-2 CS cells with
MG132 and epoxomicin, respectively, returned the HIF-1a level
back to the same level as in hypoxic SHP-2WT cells treated with pro-
teasome inhibitors (p < 0.05, n = 3–4; Figure 2C). Inhibition of PHD
activity by desferrioxamine (DFO) in SHP-2 CS expressing cells also
returned the decreased HIF-1a protein level back to levels seen in
hypoxic SHP-2 WT cells (p < 0.05, n = 4; Figure 2D). In addition, a
stronger HIF-1a prolyl hydroxylation was detected in SHP-2 CS cells
compared to SHP-2 WT cells upon MG132 treatment prior toMolecular Therapy Vol. 25 No 7 July 2017 1617
Figure 1. SHP-2 Inactivation Inhibits Hypoxia-Induced
Angiogenesis and HIF-1a Accumulation and Activity
In Vitro
(A) Overexpression of SHP-2 WT, SHP-2 CS (dominant
negative mutant), or SHP-2 E76A (constitutively active
mutant) was achieved by lentiviral transduction (see Fig-
ure S1). Proliferation of endothelial cells expressing the
different SHP-2 constructs upon 24 hr hypoxia treatment
was assessed by MTT reduction 96 hr post transduction
(*p < 0.05, n = 5 in triplicates). The enhanced proliferation in
SHP-2 E76A cells was inhibited by treatment with 10 ng/mL
echinomycin (Ecm) (p < 0.05, n = 5 in triplicates). (B) For-
mation of capillary like structures in Matrigel during hypoxia
(24 hr) in SHP-2 WT, CS, and E76A expressing endothelial
cells (*p < 0.05, n = 5 each, 4 fields of view). The Matrigel
assay was performed 96 hr after lentiviral transduction. (C)
Vessel sprouting from aortic rings ex vivo expressing SHP-2
WT, CS, or E76A and exposed to hypoxia (24 hr) (*p < 0.05,
n = 4–5). The isolated vessels were immediately transduced
using magnetic targeting of MNP-LV complexes to the
vessel wall. At 48 hr later, aortas were cut into rings,
embedded in Matrigel, and exposed to hypoxia. (D) Hyp-
oxia-induced (4 hr) VEGF production from SHP-2 WT, CS,
or E76A expressing endothelial cells, as assessed by ELISA
96 hr after transduction (*p < 0.05, n = 3–6). (E) Analysis of
hypoxia-induced (4 hr) HIF-1a accumulation in endothelial
cells lentivirally transduced with SHP-2 WT, CS, E76A, or
Y2F. The graph shows protein band densities of HIF-1a
normalized to actin (*p < 0.05, n = 6). (F) HIF-1 DNA binding
activity in nuclear extracts of cells expressing SHP-2 WT or
CS upon hypoxia (4 hr) was measured using a HIF-1 tran-
scription factor assay kit 96 hr post transduction (*p < 0.05,
n = 3 in duplicates). (G) HIF-1a activity upon hypoxia (4 hr) in
endothelial cells expressing SHP-2 WT or CS was detected
72 hr upon co-transduction of SHP-2 WT or CS in combi-
nation with the HIF1-TRE-Luc or Control-Luc reporter
construct (*p < 0.05, n = 5). All of the quantitative data are
represented as mean ± SEM.
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Figure 2. SHP-2 Inhibits HIF-1a Degradation via
Activation of the Src Kinase
(A) Hypoxic (4 hr) HIF-1a mRNA expression in cells
overexpressing SHP-2WT, CS, or E76Awas assessed by
qRT-PCR 96 hr post transduction (n = 3 in duplicates). (B)
Live cell HIF-1a mRNA detection in hypoxic (4 hr) cells
expressing SHP-2 WT-IRES-eGFP, CS-IRES-eGFP, or
E76A-IRES-eGFP, using HIF-1a or scramble (control)
SmartFlare probes and flow cytometry 96 hr post trans-
duction (n = 3 in duplicates). The graph shows HIF-1a
mRNA in GFP positive cells. (C) MG132 (10 mM) or ep-
oxomicin (1 mM) treatment increased HIF-1a levels in
SHP-2 CS expressing cells (lanes 7–9) to the same extent
as in SHP-2WT cells under hypoxia (4 hr) (lanes 4–6) (*p <
0.05, n = 3–7), as assessed by western blot. (D) HIF-1a
levels in DFO treated (100 mM) SHP-2 WT or CS ex-
pressing cells during hypoxia (4 hr) (*p < 0.05, n = 4). (E)
Prolyl-hydroxylated HIF-1a (Pro564) was analyzed in
SHP-2 WT, CS, and E76A cells after hypoxia (4 hr) and
MG132 (10 mM) treatment by western blot (*p < 0.05,
n = 3). The graphs belowblots showprotein band densities
of HIF-1a normalized to actin. (F) Hydroxylation of HIF-1a
in endothelial cells during hypoxia (4 hr) upon treatment
with Src inhibitor (100 nM PP2) and exposure to MG132
(10 mM) (*p < 0.05, n = 3) was detected using western blot.
The graph shows protein band densities of hydroxy-
HIF-1a normalized to actin. (G) Hypoxia- (4 hr) induced Src
phosphorylation in cells expressing SHP-2 WT, CS, or
SHP-2 E76A was analyzed by western blot 96 hr post
transduction (*p < 0.05, n = 4–7). The graph shows protein
band densities of phospho-Src normalized to actin. See
also Figure S2. (H) The influence of hypoxia (4 hr) on SHP-2
phosphatase activity was measured by dephosphorylation
of pNPP in SHP-2 precipitates (**p < 0.01, n = 6). All of the
quantitative data are represented as mean ± SEM.
www.moleculartherapy.orghypoxia (p < 0.05, n = 3; Figure 2E). As the activation of Src kinase has
been shown to rely on SHP-2 activity upon growth factor stimula-
tion,26 we next investigated if SHP-2, in addition, influences Src acti-M
vation under hypoxia. First, Src inhibition
increased HIF-1a hydroxylation in cells treated
with MG132 under hypoxic conditions (p <
0.05, n = 3; Figure 2F), indicating a similar pro-
tective effect as SHP-2 from HIF-1a degrada-
tion. Next, Src activation was shown to be
dependent on SHP-2 activity, as this was
reduced in SHP-2 CS expressing cells and
enhanced in SHP-2 E76A expressing cells
compared to SHP-2 WT expression under hyp-
oxic conditions (p < 0.05, n = 4–7; Figure 2G). A
reduction in phosphorylation of other Src
kinase family members could also be observed
in SHP-2 CS expressing cells compared to
SHP-2 WT upon a phospho-Src kinase screen
(Figure S2). As we observed that SHP-2 pro-
motes HIF-1a stabilization and activity as well
as Src kinase signaling and angiogenesis uponhypoxia, we next measured endogenous SHP-2 phosphatase activity
upon hypoxia. As seen in Figure 2H, hypoxia significantly increased
SHP-2 activity (p < 0.01, n = 6).olecular Therapy Vol. 25 No 7 July 2017 1619
Molecular TherapyMagnetic Targeting of MNP-LV Complexes Accomplishes
Simultaneous but Differential Gene Expression at Defined Sites
in the Dorsal Skin of Mice
As we aimed at investigating the role of SHP-2 in HIF-1a dependent
angiogenesis, we first assessed vessel outgrowth in an in vivo wound
healing model over a period of time using the mouse dorsal skinfold
chamber. This was enabled by intravenous injection of FITC-Dextran
followed by intravital fluorescent microscopy (p < 0.05 versus first
observation time point, n = 3 animals; Figure 3A). In order to later
study the effect of SHP-2 phosphatase activity in this in vivo wound
healing model to elucidate its potential as a therapeutic target, we es-
tablished a localized transduction technique to the dorsal skin by us-
ing lentiviral particles associated to MNP and achieved their targeting
to the dorsal skin by exposure to amagnetic field. As seen in Figure 3B,
magnetic targeting of a luciferase expressing lentivirus associated to
MNP resulted in local luciferase expression in the targeted dorsal
skin. In fact, no transgene expression was detected at any other site,
demonstrating the local specificity of the technique (Figure S3).
Moreover, no reporter gene expression was observed in the absence
of a magnetic field (Figure 3B). To elucidate if magnetic targeting
of MNP-LV complexes and the resulting gene expression influences
the wound healing response per se, MNP associated to SHP-2WT ex-
pressing lentivirus was targeted to wounds of the dorsal skin and
compared to non-treated wounds. As seen in Figure 3C, no difference
between the two groups was observed (n = 3-7 animals). Importantly,
we were able to achieve independent local transduction of up to three
areas within the same dorsal skinfold chamber using this technique,
as seen by the differential gene expression strength, which correlated
well with the amount of applied lentiviral particles (Figure 3D).
Importantly, there was no contamination between the different
wounds, as only the wound exposed to MNP-LV complexes in com-
bination with a MF expressed the transgene, although other wounds
treated with only sodium chloride in the same dorsal skinfold cham-
ber were exposed to the MF (Figure 3E). Furthermore, magnetic tar-
geting of MNP and LV expressing SHP-2 WT and td Tomato via an
IRES sequence showed that gene expression could be directed with
high precision to the wound area (Figure 3F; n = 3).
Genetic Modulation of SHP-2 Phosphatase Activity by Magnetic
LV-MNP Targeting Controls HIF-1a Dependent Wound Healing
Angiogenesis In Vivo
Having observed that SHP-2 affects hypoxic HIF-1a accumulation
and activity in vitro, we next investigated if SHP-2 has the same effect
in vivo. In order to precisely visualize the induction of HIF-1 tran-
scriptional activity in wounds in vivo, the lentiviral HIF1-transcrip-
tional reporter construct HIF1-TRE-Luc or control reporter construct
Control-Luc was delivered to individual wounds in the dorsal skinfold
chamber by local magnetic targeting of MNP-LV complexes (Fig-
ure 4). Only weak bioluminescence signals could be detected in
HIF1-TRE-Luc transduced intact areas or wounds transduced with
Control-Luc (n = 8 animals; Figure 5A). In contrast, high and local
HIF-1 activity was detected within the wound area, as indicated by
HIF-1 dependent luciferase expression (p < 0.05, n = 8 animals; Fig-
ure 5A), verifying the relevance ofHIF-1a for wound healing. Further-1620 Molecular Therapy Vol. 25 No 7 July 2017more, overexpression of SHP-2 CS in wounds, using magnetic
targeted transduction, impaired vessel outgrowth and thus wound
healing compared to SHP-2 WT overexpression (p < 0.05, n = 5 ani-
mals; Figures 4 and 5B). In contrast, overexpression of SHP-2 E76A in
the wound significantly accelerated vessel outgrowth and thus wound
closure (p < 0.05, n = 5 animals; Figure 5B). To verify the influence of
SHP-2 on HIF-1a activity in vivo, three individual wounds within one
dorsal skinfold chamber were simultaneously co-transduced with the
different lentiviral SHP-2 mutants and the HIF1-TRE-Luc reporter or
Control-Luc reporter construct using MNP mediated targeting,
respectively (Figure 4). While no luciferase expression could be de-
tected in wounds co-transduced with the different SHP-2 constructs
and the Control-Luc reporter construct lacking the HIF-1 TRE
sequence, wounds co-expressing SHP-2 WT/HIF1-TRE-Luc showed
strong luciferase activity resulting from endogenous HIF-1a accumu-
lation in the wound (Figure 5C). However, in wounds with localized
SHP-2 CS/HIF1-TRE-Luc expression, only weak luciferase activity
was detected indicating diminished HIF-1a accumulation (p < 0.05,
n = 4; Figure 5C). In contrast, SHP-2 E76A expression further
enhanced HIF-1a transcriptional activity in hypoxic wounds in vivo
compared to SHP-2 WT (p < 0.05, n = 4 animals; Figure 5C). More-
over, whereas the mRNA of the HIF-1a target genes VEGF-A,
PDGF-B, andMMP-2 were increased in wounds compared to healthy
surrounding tissue (p < 0.05, n = 5; Figure 5D), expression of SHP-2
CS in wounds reduced mRNA expression of these genes compared to
wounds expressing SHP-2 WT (p < 0.05, n = 3–5; Figure 5D).
DISCUSSION
Hypoxia induces vascularization by stabilizing HIF-1a leading to
transcription of angiogenic factors. Hypoxia dependent vessel forma-
tion is an important feature in several medical conditions, such as
tumor growth, diabetic retinopathy, and ischemia, and efforts have
been made to reverse the disease phenotype by targeting HIF-1a.13
In this study, we demonstrate that the tyrosine phosphatase activity
of SHP-2 positively influences hypoxia dependent angiogenesis
in vitro as well as in vivo by supporting stabilization and accumula-
tion of HIF-1a. Thus, we identify SHP-2 as a potential therapeutic
target for modulating HIF-1a dependent vascularization. By intro-
ducing the expression of SHP-2 mutants in wounds using magnetic
targeting of MNP-LV complexes, wound healing angiogenesis can
be controlled site-specifically in vivo.
Our data reveal that SHP-2 is essential for the angiogenic response of
endothelial cells under hypoxic conditions, as well as for wound heal-
ing angiogenesis in vivo, where hypoxia is the major driving factor.27
This is in accordance with the impaired vessel formation of the
chicken chorioallantoic membrane observed after SHP-2 pharmaco-
logical inhibition from an earlier study by us,22 further emphasizing
a promoting role of SHP-2 in vessel growth. In fact, here, we found
SHP-2 phosphatase activity to affect hypoxic angiogenesis by
increasing HIF-1a protein levels, HIF-1a DNA binding activity,
as well as HIF-1a transcriptional activity, resulting in production
of angiogenic factors, such as VEGF-A, PDGF-B, and MMP-2.
We demonstrate that SHP-2 promotes HIF-1a accumulation by
(legend on next page)
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Molecular Therapyinhibiting its degradation via a Src kinase dependent mechanism, as
proteasome as well as PHD inhibition rescued the lowHIF-1a protein
levels in SHP-2 CS expressing cells. The detection of stronger HIF-1a
prolyl hydroxylation in these cells confirms these findings. Of note,
the influence of SHP-2 on HIF-1a accumulation and activity was
shown to indeed be physiologically relevant, as modulation of
SHP-2 activity in wounds in mice regulated local HIF-1a activity
and consequentially the expression of HIF-1a target genes in these
wounds, thus controlling the wound healing response. Most excit-
ingly, by using our magnetic gene targeting technique, we were able
to induce expression of a desired gene with high precision to a specific
site, the wound, and did thereby not only confirm the SHP-2 depen-
dent mechanism observed in vitro in an equivalent and physiologi-
cally relevant in vivo set up, but also demonstrate the therapeutic
potential of SHP-2 for angiogenesis. Furthermore, the observation
that SHP-2 activity is increased under hypoxic conditions strongly
arguments for a physiologically relevant and promoting role of
SHP-2 in HIF-1a dependent angiogenesis. Thus, our findings un-
cover a so far unrecognized, but significant, role of SHP-2 for hypoxic
angiogenesis determining HIF-1a accumulation and activity.
For patho-physiological conditions with impaired wound healing and
decreased HIF-1a expression, such as diabetic wounds,28,29 as well as
for conditions with enhanced vascularization, such as tumors ex-
pressing high levels of HIF-1a,13 controlling SHP-2 activity may
improve disease. Indeed, this was demonstrated by our in vivo tech-
nique using magnetic targeting of MNP-LV complexes to individual
wounds of the mouse dorsal skinfold chamber. This elegantly did not
only allow direct measurement of HIF-1a activity in the wound by
transduction of a HIF1-TRE reporter construct, but additionally em-
powered simultaneous expression of different SHP-2 gene constructs
inducing enhanced as well as decreased HIF-1a expression and
wound healing responses, respectively, in defined regions of the
same tissue in one animal. Thus, HIF-1a expression in wounds in vivo
can indeed be controlled by genetic modulation of SHP-2 activity.Figure 3. Magnetic Mediated MNP-LV Gene Delivery Allows for Gene Expressi
(A) Time course of wound closure of the subcutaneous layer in themouse dorsal skinfold
dorsal skin of mice waswounded using a hot probe and wound size was detected by FIT
representative intravital microscopy images of wounds after FITC-Dextran injection for
marks initial wound area as measured on day 3 (first measurement). The bar in photos re
associated to MNP resulted in local luciferase expression only when a magnetic field
(photons/sec) was determined using region of interest (ROI) measurements. The biolumi
post transduction. See also Figure S3. (C) Comparison in wound healing response b
targeting of MNP associated to lentivirus expressing SHP-2WT (gray bars). The fluoresce
by injection of FITC-Dextran. The wound closure at day 9 was normalized to day 3 of
croscopy images of wounds after FITC-Dextran injection are shown (right). The white do
bar in photos represents 500 mm. (D) Magnetic targeting ofMNP associated to different le
same dorsal skinfold chamber correlates with the respective different luciferase expressio
were performed 6 days post transduction. (1) application of 1  106 VP; (2) applicatio
associated to a luciferase expressing lentivirus to a wound induces expression of the t
wounds of the same dorsal skinfold chamber treated with only sodium chloride solut
(F) Intravital microscopy images of wounds after FITC-Dextran injection (green) and mag
via an IRES element showing transgene expression in the wound (red) 6 days after tr
represented as mean ± SEM.
1622 Molecular Therapy Vol. 25 No 7 July 2017Therefore, this technique may be of great therapeutic interest, as it en-
ables the selective interference with angiogenic processes in defined
areas exclusively. The ability to design magnetic fields with powerful
enough field gradients to reach distant and deeper situated sites will
determine the actual potential and the extent of translation of this
technique into the clinic.
In summary, we did not only achieve desired differential gene expres-
sion at defined sites of the same tissue by using magnetic targeting of
MNP and lentiviral particles, but we also unveil a decisive role of
SHP-2 in promoting the stabilization and activation of HIF-1a upon
hypoxia through Src signaling, thereby having an essential impact
on hypoxia and HIF-1a dependent angiogenesis in vitro and in vivo.
Thus, modulation of SHP-2 activity and so HIF-1a accumulation in
diseased areas by magnetic targeting may be a powerful tool to
improve patho-physiological conditions involving vascularization.
MATERIALS AND METHODS
Antibodies and Chemicals
Hydroxy-HIF-1a (Pro564) (#3434), phospho-Src (Y416) (#2101),
myc-tag (#2276), and b-Actin (13E5) (#4970) antibodies were from
Cell Signaling Technology. HIF-1a clone H1a67 (#MAB5382),
HIF-1a clone EP1215Y (#04-1006), anti-mouse (#401253), and rabbit
(#401353) horseradish peroxidase-conjugated secondary antibodies
were from Merck Millipore. Epoxomicin and PP2 were from Calbio-
chem. Luciferin was purchased from Promega. All other chemicals
were from Sigma-Aldrich.
Human Microvascular Endothelial Cell Culture
Human microvascular endothelial cell (HMEC) were cultivated as
previously described.30
Lentiviral Constructs and Transductions
Plasmid vectors of WT SHP-2 and the catalytically inactive mutant
SHP-2 CS (Cys459 to Ser459) were kind gifts from the Bennetton in Wounds in the Dorsal Skin of Mice
chambermodel (*p < 0.05 versus time point of first measurement, n = 3 animals). The
C-Dextran injection and fluorescent intravital microscopy at denoted time points. The
visualization of vessel growth into wounds are shown (right). The white dotted line
presents 500 mm. (B) Application of luciferase expressing lentiviral particles (Luc LV)
(MF) was applied to the dorsal skinfold chamber (right). The total photon flux (TF)
nescence measurements by intraperitoneal luciferin injection were performed 6 days
etween non-treated (no MNP-LV; white bars) wounds and wounds with magnetic
nt intravital microscopywas performed 3 and 9 days post transduction, respectively,
the respective wound. ns: not significant, n = 3–7. The representative intravital mi-
tted line marks the initial wound area as measured on day 3 (first measurement). The
ntiviral particle amounts (VP) of luciferase expressing lentivirus to defined areas of the
n strength. The bioluminescencemeasurements by intraperitoneal luciferin injection
n of 5  106 VP; and (3) application of 1  107 VP. (E) Magnetic targeting of MNP
ransgene 6 days after transduction, whereas no expression was detected in other
ion and exposed to the magnetic field (MF). The dotted circles mark the wounds.
netic targeting of MNP associated to lentivirus expressing SHP-2WT and td Tomato
ansduction. The bar in photos represents 500 mm. All of the quantitative data are
Figure 4. Scheme of Site-Specific Expression of SHP-2 Mutants and HIF1-TRE-Luc in Wounds in the Dorsal Skinfold Chamber in Mice
Day 1: Preparation of the dorsal skinfold chamber on C57BL/6J mice. Day 0: Up to three wounds were induced within the observation window using a heated wire. Day 1:
Lentiviral vectors carrying expression vectors for SHP-2 mutants (WT, CS, and E76A), HIF1-TRE-Luc, or Control-Luc, respectively, were associated to magnetic nano-
particles10 and individually applied to the wounds under magnetic field exposure. Day 3: First measurement of wound size and vessel growth within the wound by intravenous
injection of FITC-Dextran and intravital microscopy. Day 6: Measurement of wound size and vessel growth within the wound by intravenous injection of FITC-Dextran and
intravital microscopy (SHP-2 WT, CS, and E76A) or detection of bioluminescence in wounds (HIF1-TRE-Luc and Control-Luc).
www.moleculartherapy.orglaboratory,31 the tyrosine phosphorylation sites SHP-2 mutant (Y2F),
used to analyze involvement of SHP-2 phosphorylation, was kindly
provided by Professor F. Schaper at Magdeburg University, Germany.
Mutation of Glu76 to Ala76 to generate the constitutively active
SHP-2 E76A was produced using the SHP-2 WT vector and the
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent) according
to the manufacturers’ instructions. The different cDNAs were subcl-
oned into a self-inactivating RRL-lentiviral backbone (pcDNA3) un-
der control of a CMV-promoter with IRES-GFP or IRES-td Tomato
co-expression. The HIF1-TRE-Luc lentiviral plasmid was obtained
from System Biosciences (pGreenFire1-HIF1). The control lentiviral
plasmid (Ctrl-Luc) was generated by excision of the TRE-sequence
from the HIF-TRE-Luc lentiviral plasmid using EcoRI and SpeI,
followed by generation of blunt ends and fill-in using Klenow Large
DNA polymerase I and religation. Sequences were verified by DNA
sequencing. Lentiviral particles were produced as previously
described.11 The biological titer was determined by flow cytometry
of transduced HEK293T cells as described elsewhere.11 Lentiviraltransduction of HMECs was performed using a multiplicity of infec-
tion (MOI) of 5. Lentiviral particles were diluted in Hank’s solution
and applied onto subconfluent HMEC. After incubation for 4–6 hr
at 37C, culture medium was added and medium was changed the
next day. Cells were left 72 hr before assaying.
Hypoxia Treatment
HMECs were exposed to hypoxia (pO2 8 ± 2 mmHg equivalent to a
O2 concentration of 1 ± 0.2%) for indicated times in a hypoxia cham-
ber (Cell Systems) as previously described.32
Quantitative Real-Time PCR
Total RNA from HMEC was isolated and quantitative reverse-tran-
scriptase PCR (qRT-PCR) of HIF-1a RNA was performed as
described before.32 To isolate total RNA from mouse tissue, wound
or healthy areas were excised and mechanically ground in RNA lysis
buffer by using Precellys ceramic beads (PEQLAB). qRT-PCR was
performed as described before32 using the following primersMolecular Therapy Vol. 25 No 7 July 2017 1623
(legend on next page)
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www.moleculartherapy.org(Metabion): VEGF fw: TATTCAGCGGACTCACCAGC and rv: AA
CCAACCTCCTCAAACCGT;MMP2 fw: TCTGCGATGAGCTTAG
GGAAAC and rv: GACATACATCTTTGCAGGAGACAAG PDGF-B
fw: AAGTGTGAGACAATAGTGACCCC and rv: CATGGGTGTGC
TTAAACTTTCG; and Ribosomal protein S18 fw: GTTCCAGCA
CATTTTGCGAGT and rv: GAGTTCTCCAGCCCTCTTGG.
Live Cell HIF-1a RNA Detection with SmartFlare Probes
Detection and quantification of HIF-1amRNA in live cells expressing
different SHP-2 constructs coupled to an IRES-GFP cassette were
performed using HIF-1a and scrambled SmartFlare probes and
flow cytometry according to the supplier’s protocol (Invitrogen). In
detail, cells were transduced with SHP-2WT, CS, or E76A expressing
lentivirus and seeded on to 96-well plates. 72 hr later, cells were incu-
bated with the HIF-1a probe or a scrambled probe (SF-102) as control
2 hr prior to hypoxia treatment to allow for efficient uptake of the
probes. After 4 hr of hypoxia, cells were immediately analyzed
by flow cytometry. Detection of SmartFlare probes was only
performed in cells positive for GFP (SHP-2 WT, CS, and E76A ex-
pressing cells) as determined by flow cytometry. A fluorescent probe
(SF-137) was used to control for SmartFlare uptake.
Detection of VEGF Production
VEGF-A concentrations in cell supernatants were detected by Quan-
tikine ELISA (#DVE00, R&D Systems) according to the supplier’s
protocol.
Immunoblotting
Lysates were prepared and subjected to SDS-PAGE following western
blotting as described elsewhere.33 Protein band intensities were
measured using the Hokawo software (Hamamatsu).
Wound Healing Assay In Vivo and Lentiviral Magnetic Targeting
Animal studies were conducted in accordance with the German ani-
mal protection law and approved by the district government of upper
Bavaria (Regierung von Oberbayern, approval reference number
AZ55.2-1-54-2532-172-13). The investigation conforms to the Guide
for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996). Mice (C57BL/6J; Charles River) were anesthetized (5 mg/kgFigure 5. SHP-2 Activity Is Necessary for HIF-1a Dependent Angiogenesis In V
(A) HIF-1a expression and activity in wounds were detected by local expression of a lent
and compared to transduction of a control luciferase reporter construct missing the HIF
image of luciferase activity in wounds of the dorsal skinfold chamber after magnetic assis
1: HIF1-TRE-Luc transduction without wounding; 2: Control-Luc transduction of wound
E76A expression in the wound area on vessel growth and wound closure (*p < 0.05,
targeting of MNP-LV complexes. The wound sizes were normalized to respective wound
injection of FITC-Dextran at day 3 and 6 after wounding showing the vessel growth into
separate wounds are shown (right). The white dotted lines mark the initial wound area of
(C) Luciferase expression and thus HIF-1a transcriptional activity 6 days post co-trans
mouse dorsal skinfold chamber by magnetic targeting of MNP-LV complexes (*p < 0.05
wounds transduced with control-Luc (left) or HIF1-TRE-Luc (right) vectors in combina
VEGF-A, PDGF-B, and MMP-2 was measured in wounds and healthy tissue of the m
expressing SHP-2 WT or SHP-2 CS (right graph) (*p < 0.05, n = 3–5). All of the quantitmidazolam, 0.5 mg/kg medetomidin, and 0.05 mg/kg fentanyl) and
the dorsal skinfold chamber was implanted as described elsewhere.34
Up to three wounds were induced within the observation window of
one DSFC 24 hr after implantation. In detail, a heated wire (1 mm
diameter) was applied at an avascular area of the internal skin side
for 5 s. The resulting wound (2 mm diameter) was moistened
following induction of the next wound. Distinct gene expression
within the different wounds was achieved by MNP assisted lentiviral
transduction 24 hr after wound induction. The lentiviral vectors
(1.5  107 VP HIF1-TRE-Luc, control-Luc, or SHP-2 WT/CS/
E76A) were incubated separately or in the indicated combinations
with 1 mg SO-Mag MNPs35 for 10 min to allow for association. To
achieve individual transductions, a cylindrical permanent magnet
(diameter 3 mm, height 15 mm; 1,120 mT) was placed under the
respective wound and lentivirus-MNP-complexes were applied on
top. The magnetic field was applied for 5 min before the next wound
was transduced successively. After removing the magnetic field, the
dorsal skin was washed with 0.9% sodium chloride solution and the
observation window was tightly closed with a coverslip. For measure-
ment of wound areas, mice were restrained in plexiglass tubes and
20 mL FITC dextran (150 kDa, 5% in NaCl) were injected intrave-
nously via the tail vein. Images were taken using an intravital fluores-
cence microscope (Zeiss) and avascular wound areas were measured
using the AxioVision software (Zeiss). Bioluminescence imaging was
performed using an IVIS imaging system (PerkinElmer) 6 days after
magnetic targeting by intraperitoneal injection of 100 mL (3 mg/mL in
0.9% NaCl) Luciferin.
HIF-1a DNA Binding Activity
Specific HRE binding activity of HIF-1a was measured in nuclear ex-
tracts of HMECs using the Transcription Factor Assay Kit (#KA1321)
from Abnova, following manufacturer’s instructions.
Aortic Ring Sprouting Assay
Aortas were isolated from euthanized mice as previously described.22
Whole aortas were transduced with SHP-2 lentiviral particles using
the magnetofection technique.10 In detail, lentiviral particles were
incubated with PEI-Mag2 MNP (300 fg/VP) in Hanks balanced salt
solution for 20 min at room temperature. Aortas were cannulized
at both ends, flushed with lentiviral-MNP complexes, and placedivo
iviral HIF-1 transcriptional luciferase reporter construct (HIF1-TRE-Luc) in the wound
1-TRE (Control-Luc) (*p < 0.05, n = 8 animals). The representative bioluminescence
ted transduction with HIF1-TRE-Luc and Control-Luc, respectively, is shown (right).
; and 3: HIF1-TRE-Luc transduction of wound. (B) Influence of SHP-2 WT, CS, and
n = 5 animals). The expression of SHP-2 constructs was achieved using magnetic
s from day 3. The representative intravital microscopy images taken after intravenous
the wounds of one animal simultaneously expressing different SHP-2 constructs in
the respective wound as measured on day 3. The bar in photos represents 500 mm.
duction of HIF1-TRE-Luc and different SHP-2 mutant constructs in wounds in the
, n = 4 animals). The representative bioluminescence images next to the graph show
tion with SHP-2 WT and mutant constructs, respectively. (D) mRNA expression of
ouse dorsal skin by qRT-PCR (left graph) (*p < 0.05, n = 5), as well as in wounds
ative data are represented as mean ± SEM.
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Molecular Therapyon top of a permanent magnet for 30 min in medium containing 10%
FCS and 1% Pen-Strep at 37C in a humidified incubator with 5%
CO2. Aortas were then left for 48 hr to allow for SHP-2 mutant
gene expression, cut into rings, and embedded in growth factor
reduced Matrigel (BD Biosciences) followed by exposure to hypoxia
for 24 hr to allow for HIF-1a expression. At 72 hr later, images
were taken with a Zeiss Axiovert 200Mmicroscope and the sprouting
evaluated as previously described.22
Proliferation Assay
Proliferation was measured after 24 hr of hypoxia exposure using the
MTT assay as previously described.22
SHP-2 Phosphatase Activity Assay
300 mg of total protein was used for precipitation of SHP-2 with a
mouse anti-human SHP-2 (B-1) antibody. SHP-2-antibody com-
plexes were precipitated using mMACS Protein G MicroBeads and
mMACS separation columns from Miltenyi Biotec. Precipitated
SHP-2 was washed with phosphatase buffer (24 mM HEPES,
120 mM NaCl, and pH 7.4) and phosphatase activity was detected
by incubation in phosphatase buffer containing 10 mM of the chro-
mogenic substrate p-nitrophenyl phosphate (pNPP) for 1 hr at
37C in the dark. Supernatants from the precipitations were collected
and the extinction was measured at 405 nm (SpectraFluor, Tecan).
Statistical Analysis
Data are presented as means ± SEM. Statistical analyses were per-
formed with Sigma Plot 10.0. For comparisons between two groups
of normal distributed data the student’s t test was used. For multiple
comparisons the one-way ANOVA was performed. Differences were
considered significant at an error probability level of p < 0.05.
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